301080.SHE Acrobiosystems Co.Ltd.
- Market cap
- CNY 17.3B
- P/E
- 89.2x
- P/B
- 6.32x
- ROE
- 7.8%
- Dividend yield
- 0.49%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301080.SHE undervalued?
Graham numberThe Graham number of Acrobiosystems Co.Ltd. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Acrobiosystems Co.Ltd. fundamental analysis
No fundamental analysis for Acrobiosystems Co.Ltd. yet.
Acrobiosystems Co.Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Acrobiosystems Co.Ltd.
Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and research institutions. It provides kits, scientific services, and other related products under the Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, and GENPower brands. The company also offers cell therapies, gene therapies, therapeutic antibodies, antibody-drug conj…
Full company profileAcrobiosystems Co.Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Acrobiosystems Co.Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 103M | 246M | 385M | 474M | 544M | 645M | 838M | 1.07B |
| Gross Profit | 91.4M | 226M | 356M | 439M | 496M | 587M | 764M | 964M |
| Operating Income | 15.2M | 140M | 192M | 166M | 132M | 109M | 197M | 298M |
| EBITDA | 19.9M | 146M | 214M | 252M | 205M | 182M | 240M | 228M |
| Net Income | 11.1M | 116M | 174M | 204M | 154M | 124M | 166M | 215M |
| EPS | 0.19 | 1.29 | 1.04 | 1.21 | 0.91 | 1.03 | 0.99 | 1.28 |
| Balance Sheet | ||||||||
| Total Assets | 113M | 241M | 2.54B | 2.74B | 2.81B | 2.91B | 3.01B | 3.16B |
| Total Liabilities | 16.1M | 41.3M | 78.8M | 167M | 225M | 304M | 352M | 411M |
| Shareholders' Equity | 97.4M | 200M | 2.47B | 2.56B | 2.59B | 2.62B | 2.66B | 2.75B |
| Cash & Short-term Investments | 43.9M | 100M | 2.01B | 1.83B | 1.98B | 1.89B | 947M | 540M |
| Cash Flow | ||||||||
| Operating Cash Flow | 20.4M | 96.5M | 138M | 202M | 111M | 84.7M | 356M | - |
| Capital Expenditure | 10.1M | 15.0M | 61.7M | 284M | 129M | 167M | 205M | 183M |
| Free Cash Flow | 10.3M | 81.5M | 76.4M | -82.1M | -17.5M | -82.6M | 151M | 27.4M |
| Ratios | ||||||||
| ROE | 11.4% | 57.9% | 7.1% | 7.9% | 5.9% | 4.7% | 6.2% | 7.8% |
| ROA | 9.8% | 48.0% | 6.8% | 7.4% | 5.5% | 4.2% | 5.5% | 6.8% |
| Net Profit Margin | 10.7% | 47.0% | 45.3% | 42.9% | 28.3% | 19.2% | 19.8% | 20.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Acrobiosystems Co.Ltd. dividends
- Dividend yield
- 0.49%
- Forward dividend
- 0.60 CNY
- Payout ratio
- 51.7%
- Ex-dividend date
- Jun 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 85.6M | 0.51 | 51.7% |
| 2024 | CNY 108M | 0.90 | 87.4% |
| 2023 | CNY 120M | 0.71 | 78.1% |
| 2022 | CNY 120M | 0.71 | 58.9% |
| 2021 | - | - | - |
| 2020 | CNY 20.0M | 0.22 | 17.3% |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jul 11, 2025.
Who owns Acrobiosystems Co.Ltd.
- Insiders 48.91%
- Institutions 11.79%
- Public & others 39.31%
- Shares outstanding 167M
- Free float 91.3M
Acrobiosystems Co.Ltd. company profile
- Company name
- Acrobiosystems Co.Ltd.
- Ticker
- 301080.SHE
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 926
- Fiscal year end
- December
- Address
- Building 4, Building 5, Beijing, China, 100176
- Phone
- 86 10 5339 5173
- Website
- acrobiosystems.cn
About Acrobiosystems Co.Ltd.
Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and research institutions. It provides kits, scientific services, and other related products under the Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, and GENPower brands. The company also offers cell therapies, gene therapies, therapeutic antibodies, antibody-drug conjugates, core reagents for infectious disease research, and solutions for metabolic and autoimmune disease drug development. In addition, it provides custom reagent, assay development, and analytical services. Further, the company is involved in general business, sales and technical services of biological products, manufacture and sells medical devices, research and development of biological reagent products, business information consulting and conference, and company testing service businesses. The company's products are used in drug screening and optimization for diseases such as cancer, autoimmune diseases, cardiovascular diseases, and infectious diseases; diagnostic reagent development and optimization; preclinical and clinical trials; and drug manufacturing processes and process control. Acrobiosystems Co.,Ltd. was founded in 2010 and is based in Beijing, China.
Acrobiosystems Co.Ltd. management
5- Mr. Yiding ChenGM & Chairman of the Board · born 1977
- Mr. Tao LinDeputy GM, CFO, Chief Accountant & Secretary of the Board of Directors · born 1989
- Mr. Jingyun MiaoDeputy GM & Director · born 1978
- Ms. Xu HuangDeputy General Manager · born 1977
- Ms. Xiamin ChenDeputy General Manager · born 1976